EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Business Insider8h
Eisai, Biogen launch Leqembi in South Korea
Eisai (ESAIY) and Biogen (BIIB ... Leqembi received the Ministry of Food and Drug Safety, or MFDS, approval in May for treatment in adult patients with mild cognitive impairment due to Alzheimer’s ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
Yahoo Finance10d
Needham downgrades Biogen on slow growth of Alzheimer's drug
Investing.com - Needham downgraded Biogen Inc (NASDAQ:BIIB) on Monday, citing slower-than-expected growth for its Alzheimer's drug, Leqembi, and a lack of major catalysts over the next 12 months.
FiercePharma13d
EMA changes tune, endorses Eisai and Biogen's Leqembi in restricted Alzheimer's population
Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...
The Hindu12d
EU regulator backs Eisai-Biogen Alzheimer’s drug
The European Union’s drugs regulator on Thursday (November 14, 2024) recommended approval of Eisai and Biogen’s Leqembi for some patients with early Alzheimer’s disease, reversing its ...
EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen
(Reuters) -The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in ...
Yahoo Finance29d
Biogen Raises Forecast as Alzheimer’s Drug Leqembi Shows Signs of Growth
Biogen is banking on Leqembi helping to offset the decline of its multiple sclerosis medications. Leqembi is the first drug shown to slow progression of Alzheimer’s, the mind-robbing disease ...